Literature DB >> 22497252

Neovascularization in retinopathy of prematurity: opposing actions of neuronal factors GPR91 and semaphorins 3A.

Jean-Sébastien Joyal1, Samy Omri, Nicholas Sitaras, José-Carlos Rivera, Przemyslaw Sapieha, Sylvain Chemtob.   

Abstract

UNLABELLED: Retinopathy of prematurity (ROP) is a major cause of severe visual deficits in children. This review focuses on the role of newly identified factors from retinal neurons, which through their opposing actions on vascular development contribute to ROP. These hypoxia-generated mediators include the Krebs cycle intermediate, succinate acting via GPR91, and the neuronal guidance molecule Semaphorin 3A.
CONCLUSION: Neuron-derived factors guide retinal vascularization and are major contributors to the pathogenesis of ROP.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22497252     DOI: 10.1111/j.1651-2227.2012.02692.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

Review 1.  Genomics in the neonatal nursery: Focus on ROP.

Authors:  Mary Elizabeth Hartnett; C Michael Cotten
Journal:  Semin Perinatol       Date:  2015-10-23       Impact factor: 3.300

Review 2.  VEGF in Signaling and Disease: Beyond Discovery and Development.

Authors:  Rajendra S Apte; Daniel S Chen; Napoleone Ferrara
Journal:  Cell       Date:  2019-03-07       Impact factor: 41.582

3.  Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model.

Authors:  Lu Yang; Yue Xu; Weihua Li; Boyu Yang; Shanshan Yu; Huanjiao Zhou; Cheng Yang; Fan Xu; Jun Wang; Yi Gao; Yongsheng Huang; Lin Lu; Xiaoling Liang
Journal:  J Mol Neurosci       Date:  2014-12-02       Impact factor: 3.444

4.  Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity.

Authors:  Haibo Wang; Sarah X Zhang; Mary Elizabeth Hartnett
Journal:  JAMA Ophthalmol       Date:  2013-01       Impact factor: 7.389

5.  Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants.

Authors:  M Elizabeth Hartnett; Margaux A Morrison; Silvia Smith; Tammy L Yanovitch; Terri L Young; Tarah Colaizy; Allison Momany; John Dagle; Waldemar A Carlo; Erin A S Clark; Grier Page; Jeff Murray; Margaret M DeAngelis; C Michael Cotten
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-12       Impact factor: 4.799

6.  Impact of bronchopulmonary dysplasia on brain and retina.

Authors:  Annie Wing Hoi Poon; Emilie Xiao Hang Ma; Arul Vadivel; Suna Jung; Zehra Khoja; Laurel Stephens; Bernard Thébaud; Pia Wintermark
Journal:  Biol Open       Date:  2016-04-15       Impact factor: 2.422

7.  eNOS controls angiogenic sprouting and retinal neovascularization through the regulation of endothelial cell polarity.

Authors:  Tracy L Smith; Malika Oubaha; Gael Cagnone; Cécile Boscher; Jin Sung Kim; Yassine El Bakkouri; Ying Zhang; Rony Chidiac; Jeanne Corriveau; Chantal Delisle; Gregor U Andelfinger; Przemyslaw Sapieha; Jean-Sébastien Joyal; Jean-Philippe Gratton
Journal:  Cell Mol Life Sci       Date:  2021-12-31       Impact factor: 9.261

8.  Increased Retinal Expression of the Pro-Angiogenic Receptor GPR91 via BMP6 in a Mouse Model of Juvenile Hemochromatosis.

Authors:  Pachiappan Arjunan; Jaya P Gnanaprakasam; Sudha Ananth; Michelle A Romej; Veeranan-Karmegam Rajalakshmi; Puttur D Prasad; Pamela M Martin; Mariappan Gurusamy; Muthusamy Thangaraju; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04       Impact factor: 4.799

9.  The Utility of Frame Averaging for Automated Algorithms in Analyzing Retinal Vascular Biomarkers in AngioVue OCTA.

Authors:  Taly Gilat Schmidt; Rachel E Linderman; Margaret R Strampe; Toco Y P Chui; Richard B Rosen; Joseph Carroll
Journal:  Transl Vis Sci Technol       Date:  2019-01-18       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.